New pill could make IVF easier and more effective
NCT ID NCT07236476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an oral drug called LY01021 in about 90 women undergoing IVF or ICSI. The drug aims to prevent premature hormone surges that can disrupt egg retrieval. Researchers are testing three doses to find the best balance of effectiveness and safety, with the goal of improving pregnancy rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LY01021 (oral drug to control hormone levels during IVF)
- What this could lead to
- If successful, this could provide a more convenient oral option to prevent premature ovulation during IVF, potentially improving egg retrieval and pregnancy rates.
- What could go wrong
- This is an early phase 2 dose-finding study with only 90 participants. The drug may not work better than existing treatments, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASSISTED REPRODUCTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.